Xenon Pharmaceuticals (XENE) Projected to Post Earnings on Thursday

Xenon Pharmaceuticals (NASDAQ:XENE) is projected to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect Xenon Pharmaceuticals to post earnings of ($0.89) per share and revenue of $0.31 million for the quarter.

Xenon Pharmaceuticals Trading Up 0.9 %

Shares of XENE stock opened at $39.73 on Friday. Xenon Pharmaceuticals has a twelve month low of $35.53 and a twelve month high of $50.99. The stock has a market cap of $3.03 billion, a price-to-earnings ratio of -14.09 and a beta of 1.20. The company’s 50-day moving average price is $39.45 and its 200-day moving average price is $40.40.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 16,315 shares of Xenon Pharmaceuticals stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $40.50, for a total value of $660,757.50. Following the completion of the transaction, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at $1,267,731. The trade was a 34.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The disclosure for this sale can be found here. Insiders have sold a total of 57,492 shares of company stock valued at $2,334,969 over the last quarter. 5.52% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on XENE shares. Needham & Company LLC restated a “buy” rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft initiated coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $57.38.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.